Articles tagged with Drug Studies
Researchers will analyze human tissue samples to determine genetic predispositions to liver side effects from antiviral drugs. The study aims to identify potential genetic factors and dosing recommendations for safer treatment.
The study provides milestone data from six growth studies, revealing consistent growth trajectories among the studies. Researchers aim to develop prediction models for clinicians to optimize treatment timing and develop individualized predictions of future growth.
Researchers found that combining ticagrelor and aspirin is more effective than either medication alone in preventing another stroke in patients with heart plaque. The study showed a 27% reduction in stroke risk among these patients, highlighting the potential benefits of this combination therapy.
A novel patient engagement tool improved treatment outcomes for half of the 290 patients with heart failure, who were randomized into two groups. The study found that patients assigned to the engagement tool received better treatment and had optimized medication prescribing, which can improve patient outcomes.
A combination of remdesivir and hrsACE2 reduced SARS-CoV-2 viral load and inhibited replication in cell cultures. The therapy achieved a dual effect with low doses and lower toxicity, paving the way for clinical trials. HrsACE2 is currently being evaluated in a phase II trial involving 200 people with severe COVID-19.
Finerenone reduced the risk of heart attack, stroke, heart failure, and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes. The medication also reduced the rate of death, hospitalization for heart failure, and worsening kidney disease among these patients.
A global clinical trial led by Cleveland Clinic found that rilonacept resolved acute pericarditis episodes and reduced recurrence risk. The study showed 81% of patients on rilonacept reported no symptoms, compared to 25% on placebo.
A Portland State University study found that pharmacy dropboxes increase customer awareness of proper drug disposal and reduce improper disposal methods. The study suggests that legislation mandating dropboxes at pharmacies and industry funding for disposal are crucial to addressing this issue.
A Rutgers study found that nursing staff had the highest rate of COVID-19 infections among health care workers. Health care workers with direct patient contact and those caring for multiple patients with suspected or confirmed cases were more likely to test positive.
The SCORED and SOLOIST trials demonstrate the benefits of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease or recent worsening heart failure. These trials show significant reductions in cardiovascular events, including deaths, hospitalizations, and strokes.
A new medication, mavacamten, has been shown to reduce heart muscle thickness and improve cardiac structure and function in patients with hypertrophic cardiomyopathy. The study found significant reductions in heart mass and improvements in blood flow, exercise capacity, and markers of fibrosis.
In a new study, patients taking statins reported experiencing symptoms that were identical to those experienced while taking placebo pills. Researchers suggest that the nocebo effect may be the cause of these side effects, rather than an actual pharmacological effect of the drug.
Researchers found that 90% of symptoms reported by statin users were also experienced when taking a placebo. This suggests a psychological rather than pharmacological effect of statins. Despite concerns about side effects, half of participants restarted taking a statin medication six months after the trial.
A new fish oil-based medication, omega-3 carboxylic acids, did not decrease the risk of cardiac events compared to a placebo in a large phase III international study. The study found no significant differences in cardiovascular death or heart attack rates between the two groups.
Researchers found that rivaroxaban is comparable to warfarin in preventing events in patients with bioprosthetic mitral valves and atrial fibrillation. Rivaroxaban was also shown to be superior to warfarin for a subgroup of patients with recent mitral valve replacement.
A recent study published in Science Advances found that baricitinib treatment significantly reduces mortality in COVID-19 patients with moderate to severe symptoms. The drug, commonly used for rheumatoid arthritis, was shown to block viral entry and reduce inflammation, leading to a 71% reduction in mortality rates.
A new medication has been shown to reduce the risk of heart failure-related events in patients with reduced ejection fraction. The study found that omecamtiv mecarbil, a novel heart medicine, had a greater effect on patients with lower ejection fractions.
A clinical trial found that fluvoxamine prevented COVID-19 infections from worsening and kept patients out of the hospital. The antidepressant drug reduced inflammation and protected against serious breathing difficulties, suggesting it may be a promising treatment for mild to moderate cases of COVID-19.
Brigham researchers present findings on the effectiveness of lipid-lowering therapies in reducing cardiovascular events and deaths in both younger and older patients. Additionally, a study reveals that over 80% of heart failure patients are eligible for recently FDA-approved SGLT2 inhibitor therapy.
A clinical study found that baricitinib reduced the rate of death or invasive mechanical ventilation in patients with severe COVID-19 by roughly half. The drug also restrained high ACE2 receptor expression in liver cells, helping to reduce viral infection.
A national study published in JAMA found that hydroxychloroquine did not improve clinical outcomes for adult patients hospitalized with respiratory illness related to COVID-19. The study, which enrolled 479 patients, showed no evidence that the drug prevented death or helped patients recover more quickly.
A single daily pill combining blood pressure and cholesterol medications with or without aspirin reduced cardiovascular disease events in people at intermediate risk for heart disease. The polypill plus aspirin combination lowered cardiovascular disease by 31%, compared to the polypill alone, which reduced it by 21%.
A new study published in Science Advances suggests that a type of arthritis drug called baricitinib can reduce the risk of dying from COVID-19 among elderly patients. The study found that patients who received the drug had a 71% reduced risk of death compared to those who did not receive it.
A recent study published in JAMA found that fluvoxamine may prevent serious breathing problems in people with mild COVID-19 illness. The results show that fluvoxamine has the potential to reduce the risk of hospitalization in COVID-19 patients.
Researchers found that fluvoxamine prevented serious clinical deterioration in COVID-19 patients with mild-to-moderate disease. The study, which involved 152 patients, showed that those treated with fluvoxamine were less likely to become seriously ill and require hospitalization.
Researchers found that C-section birth doubles asthma and allergy risk, but recovery of gut microbiota by age 1 may prevent this. The study suggests restoring the perturbed microbiome could prevent asthma development in high-risk children.
Two studies suggest that older adults aged 70 and over with elevated LDL cholesterol levels have the highest incidence of heart attacks and cardiovascular diseases. Cholesterol-lowering therapies, including statins, are as effective at reducing cardiovascular events in this age group as they are in younger people.
Using FDA-approved treatments increases the likelihood of success, but many smokers still struggle to quit. New research finds e-cigarettes containing nicotine are more effective than other therapies, including nicotine-free options and behavioral counseling.
A study analyzing over 20,000 participants found that healthy lifestyle behaviors decreased the risk of death regardless of medication usage. Higher numbers of healthy habits led to lower death risks.
A study of hospitalized COVID-19 patients with atrial fibrillation/flutter found a significantly higher risk of death and ICU mortality. However, meta-analyses examining the effect of renin-angiotensin-aldosterone system inhibitors on COVID-19 outcomes showed no increased risk of contracting COVID-19 or dying from the illness.
A Rutgers study found antipsychotic prescribing in young children is declining, but doctors continue to prescribe for conditions lacking FDA approval and without recommended psychiatric consultations. The study highlights the need for safer first-line psychosocial treatments to minimize risks associated with antipsychotic treatment.
A new study shows that the introduction of new cancer drugs between 2000 and 2016 led to a significant reduction in mortality rates for patients with 15 common types of cancer, including breast, lung, and colorectal cancer. The study estimates that these drug approvals saved over 1.2 million lives during this period.
Mavacamten improves key structural abnormalities in obstructive hypertrophic cardiomyopathy, reducing obstruction to blood flow and abnormal mitral valve motion. The treatment also decreases elevated filling pressures and restores normal cardiac structure and function.
A new medication, centhaquine, has been found safe and effective in treating severe blood or fluid loss caused by trauma. The study showed significant improvements in patient outcomes, including reduced mortality rates and improved blood pressure and organ function.
A new study published in the journal Brain found that patients with Parkinson's disease who experience tremor symptoms do not benefit from dopaminergic medication on their learning abilities. In contrast, patients without tremor show improvement in reward learning and faster deterioration of cognitive abilities.
Researchers found that tocotrienols extracted from palm oil activate Nrf2 nuclear translocation and increase the antioxidant-related hepatoprotective mechanism in mice liver cells. The study also showed that the effect is dose-dependent and functionally relevant.
A two-drug combination of dapagliflozin and exenatide continues to effectively control patients' glucose levels without losing efficacy over a two-year period. The study also revealed significant improvements in blood pressure and weight, contributing to overall health.
Researchers from Florida Atlantic University argue that remdesivir is justified for compassionate use in severely ill patients with COVID-19 due to its potential benefits in reducing recovery time. Despite FDA approval, the current evidence base supports the use of other proven preventive strategies such as social distancing and masking.
A new study examines clinical trials involving radiation therapy from 1996 to 2019 and finds that Black and Asian American patients are underrepresented, with 12% and 3% of trial participants respectively. The findings highlight the need for better inclusion of racial minorities in research studies.
Researchers have improved consistency assessment in meta-analysis by considering statistical power. This new measure can alter the interpretation of meta-analyses. Studies with high statistical power should have stronger effects on results.
A randomized trial will evaluate a telehealth-delivered collaborative care model to motivate primary care patients with opioid dependence and depression to increase engagement in evidence-based treatments. The study aims to improve depression symptoms and provide pragmatic clinical approaches to address this unmet challenge.
Researchers will present on anti-amyloid treatments and new late-stage clinical trials for Alzheimer's. NIA is funding over 230 active clinical trials to support the development of new treatments.
A double-blind clinical trial investigates the effectiveness of ondansetron, a cancer anti-sickness drug, in alleviating hallucinations in people with Parkinson's. The study aims to find new treatments for this challenging symptom, which affects 75% of UK Parkinson's patients.
Adagrasib achieves objective responses in nearly half of patients with non-small cell lung cancer; encouraging early results are seen in patients with colorectal, pancreatic, and endometrial cancer. The agent targets KRAS G12C mutation, leading to manageable side effects.
A clinical trial published in the New England Journal of Medicine shows that finerenone significantly slows the progression of diabetic kidney disease by 18% compared to a placebo. The study also found a reduction in cardiovascular event rates, offering new treatment options for patients with chronic kidney disease and type 2 diabetes.
A clinical trial called REPAIR-MDS will test repurposed drugs to improve hematological responses in MDS, reducing or reversing life-limiting deficiencies in red blood cells. The trial aims to improve the outlook for people with this rare condition, which has limited treatment options.
A new patient-reported outcome measure, SONG-HD Fatigue, has been validated to assess fatigue in patients receiving long-term dialysis treatments. The instrument calculates average fatigue over a period of 1 week, gauging tiredness, energy, and impact on life participation.
A new study found that malaria-preventive drugs can dramatically reduce infections in school children by half, leading to improved learning and reduced anemia. The analysis included 15,000 schoolchildren across seven African countries and showed a significant association between preventive treatment and better health outcomes.
A new study at Boston Medical Center found that the common treatment bevacizumab for diabetic macular edema is less effective for Black patients compared to white and Hispanic individuals. This disparity underscores the importance of increasing diversity in clinical trials to develop treatments tailored to all patient groups.
Two new UT Southwestern studies report that only half of practicing physicians are registered to vote, with time being the most common barrier faced by resident physicians. The researchers say finding ways to increase voter participation among doctors is critical as the nation tackles healthcare issues.
The Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) has achieved significant milestones in its first year, thanks to data sharing and collaboration among stakeholders. The platform serves as a centralized infrastructure to support data analysis and aid in the understanding of rare diseases.
A new study published in the New England Journal of Medicine found that tocilizumab does not reduce the need for breathing assistance with mechanical ventilation or prevent death in moderately ill hospitalized patients with COVID-19. The treatment was tested on 243 patients with high levels of inflammation and pneumonia, fever, or low ...
The VOYAGER PAD trial found that drug-coated devices do not increase mortality risk in patients with peripheral artery disease. Rivaroxaban use consistently reduced ischemic limb and cardiovascular outcomes regardless of device type.
A randomized trial comparing a nano-coated coronary stent with shorter dual anti-platelet therapy (DAPT) to a drug-eluting stent (DES) with guideline-recommended DAPT duration found no reduction in bleeding or thrombotic events. The study included 996 patients and found the rate of bleeding in the test group was 7.5% compared to 8.9% i...
The OPTIMIZE trial found that the new stent did not meet non-inferiority criteria due to high TVMI rates from high-sensitivity troponin biomarkers. However, independent analyses demonstrate non-inferiority with comparable relative non-inferiority margin, suggesting potential for improved clinical outcomes
The FORECAST trial found that fractional flow reserve derived from computed tomography coronary angiography (FFRCT) reduced the use of invasive coronary angiography by 22% without significantly reducing costs. The strategy also showed promise in terms of reducing healthcare utilization and improving patient outcomes.
A recent clinical trial found that patients with ALS who received the investigational neuroprotective therapy AMX0035 lived for a median of 6.5 months longer than those who received placebo. This result demonstrates the potential to prolong patient survival and slow disease progression.
A minimum unit price for alcohol policy significantly decreases deaths and hospitalizations related to alcohol use, according to a new report. By setting a floor price for alcohol sales, such policies help prevent the sale of cheap drinks with high alcohol content.
The 38th Annual Meeting of The Obesity Society will present innovative scientific research results through oral and poster abstracts. These communications highlight new anti-obesity medication clinical trials and comparisons of weight loss diets.
A new study found that 90% of CBD users claimed to use it for medical conditions such as autism, depression, and sleep disorders. In contrast, only 30% cited wellness benefits. The study highlights the need for enhanced regulation of the CBD market to prevent patients from forgoing proven treatments.